Skip to main content
. Author manuscript; available in PMC: 2011 Dec 13.
Published in final edited form as: Biomacromolecules. 2010 Nov 8;11(12):3630–3637. doi: 10.1021/bm1010855

Fig. 9.

Fig. 9

(a) Cumulative release profiles of FITC-BSA and RhoB-gentamicin from polypeptide multilayer films with (solid symbols) and without (empty symbols) CapsulePLL and/or CapsulePLGA. FITC-BSA was released from multilayer films of (PLL/PLGA)3.5/CapsulePLL/(PLL/PLGA)10.5, (PLL/PLGA)3.5/CapsulePLGA/(PLL/PLGA)10.5, and (PLL/PLGA)3.5/PLGA/(PLL/PLGA)10.5. RhoB-gentamicin was released from multilayer films of (PLL/PLGA)3.5/CapsulePLGA/(PLL/PLGA)10.5 and (PLL/PLGA)3.5/PLGA/(PLL/PLGA)10.5. (b) Cumulative release profiles in percentage of FITC-BSA and RhoB-gentamicin from polypeptide multilayer films, i.e. (PLL/PLGA)3.5/CapsulePLL/(PLL/PLGA)10.5/CapsulePLGA/(PLL/PLGA)10.5, containing both CapsulePLL and CapsulePLGA. Inset shows the cumulative release in actual amounts. All experiments were carried out in triplicate.